X4 Pharmaceuticals, Inc Income Tax Expense (Benefit) in USD from 2018 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
X4 Pharmaceuticals, Inc quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2018 to Q3 2025.
  • X4 Pharmaceuticals, Inc Income Tax Expense (Benefit) for the quarter ending September 30, 2025 was -$30K, a 300% decline year-over-year.
  • X4 Pharmaceuticals, Inc Income Tax Expense (Benefit) for the twelve months ending September 30, 2025 was $299K, a 252% increase year-over-year.
  • X4 Pharmaceuticals, Inc annual Income Tax Expense (Benefit) for 2024 was $310K, a 297% increase from 2023.
  • X4 Pharmaceuticals, Inc annual Income Tax Expense (Benefit) for 2023 was $78K, a 179% increase from 2022.
  • X4 Pharmaceuticals, Inc annual Income Tax Expense (Benefit) for 2022 was $28K, a 64.7% increase from 2021.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)

X4 Pharmaceuticals, Inc Quarterly Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $299K -$30K -$45K -300% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-05
Q2 2025 $344K $37K +$19K +106% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-08
Q1 2025 $325K $34K +$15K +78.9% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-01
Q4 2024 $310K $258K +$225K +682% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-26
Q3 2024 $85K $15K -$11K -42.3% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-05
Q2 2024 $96K $18K +$3K +20% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-08
Q1 2024 $93K $19K +$15K +375% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-01
Q4 2023 $78K $33K +$19K +136% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-26
Q3 2023 $59K $26K +$39K Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 $20K $15K +$11K +275% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $9K $4K -$19K -82.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $28K $14K +$11K +367% Oct 1, 2022 Dec 31, 2022 10-K 2025-03-26
Q3 2022 $17K -$13K -$15K -750% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $32K $4K -$2K -33.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $34K $23K +$17K +283% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $17K $3K +$3K Oct 1, 2021 Dec 31, 2021 10-K 2024-03-21
Q3 2021 $14K $2K +$2K Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $12K $6K +$6K Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $6K $6K -$142K -95.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $148K $0 $0 Oct 1, 2020 Dec 31, 2020 10-K 2023-03-21
Q3 2020 $148K $0 $0 Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $148K $0 $0 Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 $148K $148K +$148K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $0 $0 Oct 1, 2019 Dec 31, 2019 10-K 2022-03-17
Q3 2019 $0 Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $0 Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-04
Q1 2019 $0 Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07

X4 Pharmaceuticals, Inc Annual Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $310K +$232K +297% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-26
2023 $78K +$50K +179% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-26
2022 $28K +$11K +64.7% Jan 1, 2022 Dec 31, 2022 10-K 2025-03-26
2021 $17K -$131K -88.5% Jan 1, 2021 Dec 31, 2021 10-K 2024-03-21
2020 $148K +$148K Jan 1, 2020 Dec 31, 2020 10-K 2023-03-21
2019 $0 $0 Jan 1, 2019 Dec 31, 2019 10-K 2022-03-17
2018 $0 Jan 1, 2018 Dec 31, 2018 10-K 2021-03-19
* An asterisk sign (*) next to the value indicates that the value is likely invalid.